Clinical Progression and Treatment Outcome of Multiple Myeloma
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 865
Special Issue Editors
Interests: multiple myeloma; clinical trials; immunotherapies; secondary immunodeficiency
Interests: understanding and improving health outcomes of patients with plasma cell disorders; multiple myeloma; systemic light chain amyloidosis
Special Issue Information
Dear Colleagues,
The treatment of multiple myeloma is undergoing rapid changes due to the approval of novel immunotherapies as well as novel treatment combinations. The complexity of treatment selection and sequencing has increased drastically, leaving many unanswered questions for clinicians. Clinical trials, while critically important for establishing efficacy and safety, must be complemented by real-world evidence and insights in order to gain a fuller understanding of optimal treatment selection for patients. In addition, laboratory research can provide insights into strategies to overcome or avoid treatment resistance.
We are pleased to invite you to submit your research works to this Special Issue, which aims to deepen insights into the current treatment landscape of multiple myeloma. In this Special Issue, original research articles and reviews with a focus on all treatment phases are welcome, including induction (transplant eligible/ineligible), consolidation, maintenance, early relapse, and late relapse. We are particularly interested in clinical or laboratory predictors of response, as well as mechanisms of resistance and strategies to overcome these.
We look forward to receiving your contributions.
Dr. Guido Lancman
Dr. Alissa Visram
Dr. Rayan Kaedbey
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- real-world predictors of response
- sequencing
- treatment selection
- resistance mechanisms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
